Loading
Nanoplatforms for Cancer Theranostics · Journal article
Journal of Cancer Research and Clinical Oncology · September 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing current knowledge of the CD73-adenosine pathway in NSCLC, including its role in immune regulation, mechanisms of tumor promotion, and emerging therapeutic approaches. It does not present new primary evidence or a systematic meta-analysis, but rather curates and discusses existing literature to inform clinical development of CD73-targeted therapies.
Narrative review. Non-small cell lung cancer (NSCLC).
CD73-adenosine pathway plays a key role in immune metabolic regulation in NSCLC Therapies targeting the CD73 pathway have shown significant promise in clinical trials CD73 is expressed across malignant, immune, and stromal cell populations within the tumor microenvironment
No quantitative efficacy or safety data from clinical trials reported
Clinicians and researchers should view this as a state-of-the-art synthesis supporting the rationale for CD73-targeted immunotherapies in NSCLC, particularly in combination regimens. However, specific efficacy, safety, or outcome data required for clinical decision-making are not provided in this review.
A narrative review summarizing current evidence on CD73-adenosine biology and therapeutic strategies in NSCLC, without new primary data or meta-analysis.
As stated by the source record.
Clinicians and researchers should view this as a state-of-the-art synthesis supporting the rationale for CD73-targeted immunotherapies in NSCLC, particularly in combination regimens. However, specific efficacy, safety, or outcome data required for clinical decision-making are not provided in this review.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
In non-small cell lung cancer (NSCLC), the CD73-adenosine pathway plays a key role in immune metabolic regulation. In clinical trials, therapies targeting the CD73 pathway have shown significant promise. This review summarizes the expression regulation and multidimensional pro-tumor mechanisms of the CD73-adenosine axis and the latest developments in therapies targeting CD73 in NSCLC. The review first characterizes CD73 expression in NSCLC, with particular emphasis on its distribution across malignant, immune, and stromal cell populations within the tumor microenvironment. The regulatory network governing CD73 expression is then summarized, followed by a discussion of the adenosine-dependent and adenosine-independent mechanisms through which CD73 promotes tumor progression. The biological rationale for combining CD73-targeted therapies with standard treatment regimens is also discussed. Finally, recent clinical advances in CD73-targeted therapies are reviewed, together with future research directions, including the development of dynamic biomarkers and the exploration of novel combination strategies to facilitate precision immunotherapy in NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.